

Remarks

Upon careful review of the pending Official Action, it is believed that virtually all of the pending rejections are now moot, owing to the cancellation of all pending claims and the redrafting of pending claim 85 (which was nearly in allowable form) as new claim 108 (and which takes account of the Examiner's rejections). In particular, clarifying language has been inserted into Claim 108 to show that the inhibitor compound is bound at the active site.

In regard of the *provisional* double patenting rejections, and in particular the rejection over Claim 27 of Applicant's 10/144,441 application, it is presently sufficient to note that these other applications are not yet ready to issue. Applicant agrees to consider the double patenting issues, and execute any appropriate Terminal Disclaimers, when and if double patenting actually arises, most likely at a later date in the prosecution of the other cited applications.


Applicant has cancelled all pending claims in order to facilitate examination and issuance of the present application, which is believed to be in condition for allowance. However, such cancellation neither signifies agreement nor disagreement with the rejections and objections of record, and Applicant will revisit the cancelled claims in subsequent continuation applications, to be filed in due course.

The Petition Fee of \$1,500.00, 37 CFR 1.17(m), or any other needed fee or fee amount, should be charged to Applicant's Deposit Account, No. 16-1445, and any additional fees that the Patent Office determines are needed in connection with this Petition (such as for a Petition for Extension of Time, if any) may also be charged to this Deposit Account.

An early and favorable action is respectfully requested.

Respectfully submitted,

Date: December 13, 2005

  
\_\_\_\_\_  
E. Victor Donahue, Esq.  
Attorney for Applicant(s)  
Reg. No. 35,492

Pfizer, Inc.  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-2739